Scholarlink

Abstract <p>Fine particulate matter (PM<sub>2.5</sub>), defined as airborne particles with a diameter of ≤ 2.5&#xa0;μm, represents a major constituent of air pollution and has been globally implicated in exacerbating public health burdens by elevating morbidity and mortality rates associated with respiratory and cardiovascular diseases (CVDs). Adverse health effects of PM<sub>2.5</sub> exposure manifest across diverse susceptibility profiles and durations of exposure, spanning both acute and chronic timelines. While prior reviews have predominantly focused on elucidating the toxicological mechanisms underlying PM<sub>2.5</sub>-induced pathologies, there remains a paucity of comprehensive summaries addressing therapeutic interventions for cardiopulmonary damage. This review systematically synthesizes pharmacological agents with potential therapeutic efficacy against PM<sub>2.5</sub>-induced pulmonary and cardiovascular injury. By integrating mechanistic insights with translational perspectives, this work aims to provide a foundational framework for advancing research into novel therapeutic strategies targeting PM<sub>2.5</sub>-associated cardiopulmonary disorders.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacotherapeutic Strategies for Fine Particulate Matter-Induced Lung and Cardiovascular Damage: Marketed Drugs, Traditional Chinese Medicine, and Biological Agents

  • 期刊论文

  • 发表日期：

    2025年3月20日

查看全文
  • Shuiqing Qu,
  • Yan Liang,
  • Shuoqiu Deng,
  • Yu Li,
  • Yuanmin Yang,
  • Tuo Liu,
  • Lina Chen,
  • Yujie Li

摘要

Abstract

Fine particulate matter (PM2.5), defined as airborne particles with a diameter of ≤ 2.5 μm, represents a major constituent of air pollution and has been globally implicated in exacerbating public health burdens by elevating morbidity and mortality rates associated with respiratory and cardiovascular diseases (CVDs). Adverse health effects of PM2.5 exposure manifest across diverse susceptibility profiles and durations of exposure, spanning both acute and chronic timelines. While prior reviews have predominantly focused on elucidating the toxicological mechanisms underlying PM2.5-induced pathologies, there remains a paucity of comprehensive summaries addressing therapeutic interventions for cardiopulmonary damage. This review systematically synthesizes pharmacological agents with potential therapeutic efficacy against PM2.5-induced pulmonary and cardiovascular injury. By integrating mechanistic insights with translational perspectives, this work aims to provide a foundational framework for advancing research into novel therapeutic strategies targeting PM2.5-associated cardiopulmonary disorders.

Graphical Abstract